Internist and geriatric psychiatrist, and director, Banner Alzheimer’s Institute
Aducanumab’s Implications for Future Clinical Trials: Pierre N. Tariot, MD
In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.
Biomarkers, Tech Advances to Improve Alzheimer Disease Prevention: Pierre N. Tariot, MD
The director of Banner Alzheimer’s Institute spoke on the importance of biomarkers in Alzheimer disease, as well as the ongoing improvements in digital technologies.
Conducting Alzheimer Disease Trials Remotely: Pierre N. Tariot, MD
Following the COVID-19 pandemic, investigators are seeing a shift towards remote trials in an effort to avoid participants having to be in-person at a brick-and-mortar site.
The State of Alzheimer Disease Trials: Pierre N. Tariot, MD
The director of the Banner Alzheimer’s Institute discussed areas of success and those facing challenges for Alzheimer disease clinical trials.
2 Clarke Drive Cranbury, NJ 08512